Elanco Animal Health Incorporated filed an 8-K on November 19, 2026, announcing that its Board of Directors has authorized a share repurchase program of up to $600 million of the company's common stock.

Key Highlights

  • First-ever repurchase authorization: The Board approved up to $600 million in common stock buybacks, described by the company as its first share repurchase program.
  • Net leverage milestone: The company reported its net leverage ratio (NLR) fell below 3.0x ahead of schedule, with a stated long-term target of 2.0 to 2.5 times.
  • Free cash flow progress: According to the filing, free cash flow reached $362 million as of the end of the third quarter of 2026.
  • Cumulative cash flow target: The company stated it is tracking ahead of schedule toward a cumulative free cash flow target of $1 billion from 2026 to 2028.
  • NLR reduction in 2026: The filing stated the company reduced its NLR by approximately three-quarters of a turn in 2026 year-to-date.
  • Program flexibility: The authorization does not obligate the company to acquire any specific dollar amount or number of shares and may be modified, suspended, or discontinued at any time without prior notice.

Elanco's Board Approves $600 Million Buyback as Balance Sheet Hits Sub-3x Leverage

Elanco Animal Health Incorporated (NYSE:ELAN) disclosed on November 19, 2026, that its Board of Directors authorized the repurchase of up to $600 million of its common stock. According to the filing, the authorization follows the company reaching its targeted sub-3.0x net leverage ratio faster than anticipated, which the company described as "unlocking accelerated capital allocation flexibility."

The filing stated that Elanco will continue focusing on a combination of debt paydown and accretive growth opportunities, including investment in innovation, while also executing a multi-year share repurchase program. Jeff Simmons, President and CEO, was quoted in the filing as saying that the program "reflects Elanco's financial transformation into a consistent, reliable growth company with more than three years of steady quarterly growth." The filing also attributed to Simmons expectations of "a multi-year runway of mid-single digit revenue growth, high single digit adjusted EBITDA growth and low double digit adjusted EPS growth," though the filing notes these are forward-looking statements subject to risks and uncertainties.

Bob VanHimbergen, Executive Vice President and CFO, was quoted in the filing as noting that free cash flow reached $362 million as of the end of the third quarter, with the company tracking ahead of schedule on its cumulative $1 billion free cash flow target from 2026 to 2028. The filing stated that the timing, manner, and amount of any repurchases will depend on factors including market conditions, stock price, alternative capital deployment opportunities, and applicable regulatory requirements.

What Was Disclosed

Elanco Animal Health disclosed a Board-authorized share repurchase program of up to $600 million, its first ever, following the company's net leverage ratio falling below 3.0x. The program carries no obligation to repurchase any specific amount and may be changed or stopped at any time.